Masimo Deal Approval Sets Stage For Danaher Growth And Valuation Re‑Rating

Simply Wall St.05-09

Masimo shareholders have officially approved the merger with Danaher (NYSE:DHR). The vote clears a key milestone for the acquisition and allows the deal process to move toward closing. The transaction...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2634423418?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349","is_english":true,"pubTime":"2026-05-09 18:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634423418","market":"hk","top_or_hot":-1,"title":"Masimo Deal Approval Sets Stage For Danaher Growth And Valuation Re‑Rating","media":"Simply Wall St.","content":"<div>\n<p>Masimo shareholders have officially approved the merger with Danaher (NYSE:DHR). The vote clears a key milestone for the acquisition and allows the deal process to move toward closing. The transaction...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/masimo-deal-approval-sets-stage-for-danaher-growth-and-valua\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Masimo Deal Approval Sets Stage For Danaher Growth And Valuation Re‑Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMasimo Deal Approval Sets Stage For Danaher Growth And Valuation Re‑Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-09 18:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/masimo-deal-approval-sets-stage-for-danaher-growth-and-valua><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Masimo shareholders have officially approved the merger with Danaher (NYSE:DHR). The vote clears a key milestone for the acquisition and allows the deal process to move toward closing. The transaction...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/masimo-deal-approval-sets-stage-for-danaher-growth-and-valua\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SSI","symbol_name":"Stage Stores Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/masimo-deal-approval-sets-stage-for-danaher-growth-and-valua","article_id":"2634423418","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/265621-main-header/1756203226349"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-dhr/danaher/news/masimo-deal-approval-sets-stage-for-danaher-growth-and-valua","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2634423418","pubTimestamp":1778322714,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Masimo shareholders have officially approved the merger with Danaher (NYSE:DHR).\nThe vote clears a key milestone for the acquisition and allows the deal process to move toward closing.\nThe transaction is expected to expand Danaher's presence in diagnostics and medical technology once remaining conditions are met.\n\nFor investors watching NYSE:DHR, this approval matters because it comes at a time when diagnostics, patient monitoring and broader medical technology are central to hospital and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"SSI":"Stage Stores Inc","MASI":"麦斯莫医疗","DHR":"丹纳赫"},"translate_title":"Masimo交易批准为丹纳赫增长和估值重新评级奠定了基础","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DHR":1.5,"MASI":1.5,"SSI":1.5},"content_text":"Masimo shareholders have officially approved the merger with Danaher (NYSE:DHR). The vote clears a key milestone for the acquisition and allows the deal process to move toward closing. The transaction is expected to expand Danaher's presence in diagnostics and medical technology once remaining conditions are met.  For investors watching NYSE:DHR, this approval matters because it comes at a time when diagnostics, patient monitoring and broader medical technology are central to hospital and outpatient care. Danaher already operates across life sciences, diagnostics and biotechnology tools, and Masimo's portfolio of patient monitoring and related technologies is set to broaden that footprint if the deal completes. The vote removes one major uncertainty around shareholder support and shifts attention to regulatory and closing conditions. Readers will likely focus on how quickly integration progresses after closing, how Danaher positions Masimo's products within its existing diagnostics ecosystem and what it means for capital allocation. The merger also raises questions about future R&D priorities, cross selling opportunities with hospital customers and potential changes to Danaher's competitive standing within advanced diagnostics over the long term. Stay updated on the most important news stories for Danaher by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Danaher. NYSE:DHR Earnings & Revenue Growth as at May 2026 We've flagged 0 risks for Danaher. See which could impact your investment. AdvertisementQuick Assessment  ✅ Price vs Analyst Target: At US$175.66 vs an average analyst target of US$250.14, the stock sits about 30% below consensus expectations. ✅ Simply Wall St Valuation: Simply Wall St estimates Danaher is trading 18.5% below its fair value, which supports an undervalued label. ❌ Recent Momentum: The 30 day return of about 8% decline shows recent sentiment has been soft.  There is only one way to know the right time to buy, sell or hold Danaher. Head to Simply Wall St's\ncompany report for the latest analysis of Danaher's Fair Value. Key Considerations  📊 Masimo's monitoring and medical technology portfolio could deepen Danaher's role across diagnostics and hospital workflows once the deal closes. 📊 Watch how management frames revenue synergies, integration costs and updated guidance relative to the current P/E of 33.8x and forward P/E of 26.5x. ⚠️ Integration execution is the key risk, including retaining Masimo talent, aligning product roadmaps and managing any regulatory or closing delays.  Dig Deeper For the full picture including more risks and rewards, check out the\ncomplete Danaher analysis. Alternatively, you can check out the\ncommunity page for Danaher to see how other investors believe this latest news will impact the company's narrative.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2634423418","isCrawlerRequest":true}